{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:40:32Z","timestamp":1782474032837,"version":"3.54.5"},"reference-count":128,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2026.e00839","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:10:44Z","timestamp":1770063044000},"page":"e00839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting muscarinic receptors for treating schizophrenia"],"prefix":"10.1016","volume":"23","author":[{"given":"Steven M.","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Yohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia--the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.neurot.2026.e00839_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.08.016","article-title":"Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives","volume":"131","author":"Nucifora","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","article-title":"Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors","volume":"30","author":"Valenstein","year":"2004","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ph17020178","article-title":"Antipsychotics and risks of cardiovascular and cerebrovascular diseases and mortality in dwelling community older adults","volume":"17","author":"Perreault","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1192\/bjp.bp.112.122499","article-title":"Comparative mortality risks of antipsychotic medications in community-dwelling older adults","volume":"205","author":"Gerhard","year":"2014","journal-title":"Br J Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12888-019-2177-5","article-title":"Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis","volume":"19","author":"Zivkovic","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00839_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2016.05.014","article-title":"Primary and persistent negative symptoms: concepts, assessments and neurobiological bases","volume":"186","author":"Mucci","year":"2017","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00839_bib8","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol Psychiatr"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00839_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.neurot.2026.e00839_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00839_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/nedt.2006.2.4.531","article-title":"Cognitive deficits and functional outcome in schizophrenia","volume":"2","author":"Bowie","year":"2006","journal-title":"Neuropsychiatric Dis Treat"},{"key":"10.1016\/j.neurot.2026.e00839_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurot.2026.e00839_bib13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neubiorev.2017.09.027","article-title":"Dopamine, the antipsychotic molecule: a perspective on mechanisms underlying antipsychotic response variability","volume":"85","author":"Amato","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00839_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1176\/appi.focus.18306","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"18","author":"Huhn","year":"2020","journal-title":"Focus"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/wps.21089","article-title":"Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis","volume":"22","author":"Leucht","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00839_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00839_bib17","series-title":"FDA approves drug with new mechanism of action for treatment of schizophrenia","year":"2024"},{"issue":"10422","key":"10.1016\/j.neurot.2026.e00839_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00839_bib19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00839_bib20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00839_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia:ca randomized clinical trial","volume":"81","author":"Inder","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00839_bib22","first-page":"740","article-title":"Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials","volume":"11","author":"McArthur","year":"2010","journal-title":"Curr Opin Invest Drugs"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27061816","article-title":"Role of cholinergic signaling in Alzheimer's Disease","volume":"27","author":"Chen","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib24","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.neuron.2016.09.006","article-title":"Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline","volume":"91","author":"Ballinger","year":"2016","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11357-021-00470-7","article-title":"Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary","volume":"44","author":"Balazs","year":"2022","journal-title":"GeroScience"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00839_bib26","first-page":"145","article-title":"Cholinesterase inhibitors in the treatment of dementia","volume":"105","author":"Ellis","year":"2005","journal-title":"J Am Osteopath Assoc"},{"issue":"1 Suppl 1","key":"10.1016\/j.neurot.2026.e00839_bib27","first-page":"S30","article-title":"Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease","volume":"51","author":"Taylor","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/cbdd.13958","article-title":"Synthesis and activities of acetylcholinesterase inhibitors","volume":"98","author":"Zhou","year":"2021","journal-title":"Chem Biol Drug Des"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00839_bib29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.17219\/acem\/176051","article-title":"Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: a systematic review and meta-analysis","volume":"33","author":"Gao","year":"2024","journal-title":"Adv Clin Exp Med"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00839_bib30","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2165\/00002512-199711060-00004","article-title":"Potential role of muscarinic agonists in Alzheimer's disease","volume":"11","author":"Avery","year":"1997","journal-title":"Drugs Aging"},{"issue":"208","key":"10.1016\/j.neurot.2026.e00839_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-642-23274-9_7","article-title":"Muscarinic receptor pharmacology and circuitry for the modulation of cognition","author":"Bubser","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.neurot.2026.e00839_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M(1) and M(4) receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front Psychiatr"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00839_bib34","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1021\/jm00018a007","article-title":"Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles","volume":"38","author":"Ward","year":"1995","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib35","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1038\/s41467-023-41199-5","article-title":"Xanomeline displays concomitant orthosteric and allosteric binding modes at the M(4) mAChR","volume":"14","author":"Burger","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e00839_bib36","first-page":"1","article-title":"Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines","volume":"85","year":"2004","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/ntr\/ntx187","article-title":"Cracking the betel nut: Cholinergic activity of areca alkaloids and related compounds","volume":"21","author":"Horenstein","year":"2019","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/13556210120091518","article-title":"Socio-economic aspects of areca nut use","volume":"7","author":"Croucher","year":"2002","journal-title":"Addict Biol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/13556210020091437","article-title":"Global epidemiology of areca nut usage","volume":"7","author":"Gupta","year":"2002","journal-title":"Addict Biol"},{"key":"10.1016\/j.neurot.2026.e00839_bib40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.177.2.174","article-title":"Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia","volume":"177","author":"Sullivan","year":"2000","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/08039488.2011.605172","article-title":"Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: a review","volume":"66","author":"Coppola","year":"2012","journal-title":"Nord J Psychiatr"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3565(25)38667-2","article-title":"Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors","volume":"269","author":"Shannon","year":"1994","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00839_bib43","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1021\/jm00090a019","article-title":"Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines","volume":"35","author":"Sauerberg","year":"1992","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00839_bib44","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/hipo.22732","article-title":"Effects of M1 and M4 activation on excitatory synaptic transmission in CA1","volume":"27","author":"Thorn","year":"2017","journal-title":"Hippocampus"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00839_bib45","first-page":"187","article-title":"PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man","volume":"7","author":"Farde","year":"1996","journal-title":"Dementia"},{"issue":"Suppl 4","key":"10.1016\/j.neurot.2026.e00839_bib46","first-page":"S16","article-title":"The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease","volume":"11","author":"Bodick","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00839_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0920-9964(99)00138-3","article-title":"Xanomeline, an M(1)\/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice","volume":"42","author":"Shannon","year":"2000","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02246184","article-title":"Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability","volume":"120","author":"Hoffman","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00839_bib49","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatr"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00839_bib50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd4295","article-title":"Muscarinic acetylcholine receptors: novel opportunities for drug development","volume":"13","author":"Kruse","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"34","key":"10.1016\/j.neurot.2026.e00839_bib51","doi-asserted-by":"crossref","first-page":"21563","DOI":"10.1074\/jbc.273.34.21563","article-title":"Identification of a ligand-dependent switch within a muscarinic receptor","volume":"273","author":"Spalding","year":"1998","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00839_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","article-title":"Muscarinic receptors--characterization, coupling and function","volume":"58","author":"Caulfield","year":"1993","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neurot.2026.e00839_bib53","article-title":"Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias","volume":"11","author":"van der Westhuizen","year":"2020","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: an emerging paradigm in GPCR drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"37","key":"10.1016\/j.neurot.2026.e00839_bib55","doi-asserted-by":"crossref","first-page":"15950","DOI":"10.1073\/pnas.0900903106","article-title":"Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation","volume":"106","author":"Ma","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00839_bib56","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/acschemneuro.1c00827","article-title":"Biased profile of xanomeline at the recombinant human M(4) muscarinic acetylcholine receptor","volume":"13","author":"McDonald","year":"2022","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00839_bib57","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1021\/cn500128b","article-title":"Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents","volume":"5","author":"Bubser","year":"2014","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00839_bib58","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/npp.2014.2","article-title":"Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100","volume":"39","author":"Byun","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib59","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2026.e00839_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108804","article-title":"Biased signaling in drug discovery and precision medicine","volume":"268","author":"Ji","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neurot.2026.e00839_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108786","article-title":"Biased signaling in GPCRs: structural insights and implications for drug development","volume":"266","author":"Ma","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neurot.2026.e00839_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2050-6511-13-3","article-title":"The potential for selective pharmacological therapies through biased receptor signaling","volume":"13","author":"Kenakin","year":"2012","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00839_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(09)89001-6","article-title":"Molecular profiling of striatonigral and striatopallidal medium spiny neurons past, present, and future","volume":"89","author":"Lobo","year":"2009","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.neurot.2026.e00839_bib65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2018.11.029","article-title":"The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia","volume":"146","author":"Nair","year":"2019","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00839_bib66","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1523\/JNEUROSCI.5620-09.2010","article-title":"Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum","volume":"30","author":"Threlfell","year":"2010","journal-title":"J Neurosci"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00839_bib67","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am J Psychiatr"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00839_bib68","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00839_bib69","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1113\/jphysiol.2014.275453","article-title":"Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: roles in cellular excitability, inhibitory transmission and cognition","volume":"592","author":"Yi","year":"2014","journal-title":"J Physiol"},{"key":"10.1016\/j.neurot.2026.e00839_bib70","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuroscience.2019.12.033","article-title":"Priming of GABAergic long-term potentiation by muscarinic receptors","volume":"428","author":"Morales-Weil","year":"2020","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00839_bib71","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145710001549","article-title":"The M(1)\/M(4) preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia","volume":"14","author":"Barak","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00839_bib72","first-page":"3744","article-title":"Discovery of VU6016235: a highly selective, orally bioavailable, and structurally distinct tricyclic M(4) muscarinic acetylcholine receptor Positive Allosteric Modulator (PAM)","volume":"15","author":"Engers","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00839_bib73","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1021\/acschemneuro.5c00277","article-title":"Discovery of pre-clinical candidate VU6008055\/AF98943: a highly selective, orally bioavailable, and structurally distinct tricyclic M(4) muscarinic acetylcholine receptor positive allosteric modulator (PAM) with robust in vivo efficacy","volume":"16","author":"Engers","year":"2025","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib74","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1152\/jn.00686.2010","article-title":"M1 and M4 receptors modulate hippocampal pyramidal neurons","volume":"105","author":"Dasari","year":"2011","journal-title":"J Neurophysiol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib75","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.bmcl.2015.11.053","article-title":"Design and optimization of selective azaindole amide M1 positive allosteric modulators","volume":"26","author":"Davoren","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"41","key":"10.1016\/j.neurot.2026.e00839_bib76","doi-asserted-by":"crossref","first-page":"10422","DOI":"10.1523\/JNEUROSCI.1850-08.2008","article-title":"Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats","volume":"28","author":"Jones","year":"2008","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2026.e00839_bib78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neubiorev.2021.11.034","article-title":"Structural brain correlates of cognitive function in schizophrenia: a meta-analysis","volume":"132","author":"Khalil","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.neurot.2026.e00839_bib79","first-page":"21","article-title":"Confocal analysis of cholinergic and dopaminergic inputs onto pyramidal cells in the prefrontal cortex of rodents","volume":"4","author":"Zhang","year":"2010","journal-title":"Front Neuroanat"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00839_bib80","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1096\/fj.201802351R","article-title":"M1 muscarinic receptors regulate the phosphorylation of AMPA receptor subunit GluA1 via a signaling pathway linking cAMP-PKA and PI3K-Akt","volume":"33","author":"Zhao","year":"2019","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00839_bib81","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1021\/cn500003z","article-title":"M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses","volume":"5","author":"Pancani","year":"2014","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00839_bib82","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neubiorev.2004.09.002","article-title":"An overview of the tasks used to test working memory in rodents","volume":"28","author":"Dudchenko","year":"2004","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib83","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41386-020-00916-0","article-title":"The M1\/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain","volume":"46","author":"Montani","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neulet.2010.02.031","article-title":"A novel derivative of xanomeline improves fear cognition in aged mice","volume":"473","author":"Si","year":"2010","journal-title":"Neurosci Lett"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00839_bib85","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1021\/acschemneuro.5b00123","article-title":"Role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice","volume":"6","author":"Gould","year":"2015","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00839_bib86","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0091-3057(94)00435-L","article-title":"AF150(S): a new functionally selective M1 agonist improves cognitive performance in rats","volume":"51","author":"Brandeis","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib87","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41386-023-01785-z","article-title":"Acetylcholine muscarinic M1 receptors in the rodent prefrontal cortex modulate cognitive abilities to establish social hierarchy","volume":"49","author":"Chen","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neurot.2026.e00839_bib88","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuropharm.2017.07.013","article-title":"Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M(4) PAM VU0467154","volume":"128","author":"Gould","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurot.2026.e00839_bib89","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuropharm.2017.03.017","article-title":"M(1) muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons","volume":"118","author":"Lv","year":"2017","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00839_bib90","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.conb.2011.04.004","article-title":"Cholinergic modulation of synaptic integration and dendritic excitability in the striatum","volume":"21","author":"Oldenburg","year":"2011","journal-title":"Curr Opin Neurobiol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00839_bib91","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/cne.23254","article-title":"Muscarinic cholinergic receptor M1 in the rat basolateral amygdala: ultrastructural localization and synaptic relationships to cholinergic axons","volume":"521","author":"Muller","year":"2013","journal-title":"J Comp Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00839_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045720","article-title":"Muscarinic receptors in amygdala control trace fear conditioning","volume":"7","author":"Baysinger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00839_bib93","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-6606-5-10","article-title":"M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition","volume":"5","author":"Koshimizu","year":"2012","journal-title":"Mol Brain"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00839_bib94","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/j.biopsych.2024.02.913","article-title":"Understanding the role of muscarinic M1 and M4 receptors in neural circuits that modulate negative symptoms of schizophrenia","volume":"95","author":"Yohn","year":"2024","journal-title":"Biol Psychiatry"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00839_bib95","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1021\/acs.jmedchem.4c00293","article-title":"Design and synthesis of clinical candidate PF-06852231 (CVL-231): a brain penetrant, selective, positive allosteric modulator of the M(4) muscarinic acetylcholine receptor","volume":"67","author":"Butler","year":"2024","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00839_bib96","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0026-895X(24)13285-3","article-title":"On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor","volume":"53","author":"Christopoulos","year":"1998","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00839_bib97","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/bjp.2008.152","article-title":"Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1","volume":"154","author":"Langmead","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib98","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.neurot.2026.e00839_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-025-02256-3","article-title":"Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M(1) and M(4) receptors","author":"Chatterjee","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00839_bib100","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2165\/00003495-200464210-00005","article-title":"Trospium chloride in the management of overactive bladder","volume":"64","author":"Rovner","year":"2004","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00839_bib101","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results","volume":"240","author":"Breier","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00839_bib102","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00019442-200303000-00004","article-title":"Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations","volume":"11","author":"Cummings","year":"2003","journal-title":"Am J Geriatr Psychiatr"},{"key":"10.1016\/j.neurot.2026.e00839_bib103","article-title":"An open-label extension study to assess the long-term safety and tolerability of adjunctive KarXT in subjects with inadequately controlled symptoms of schizophrenia [clinical trial]. clinicalTrials.gov identifier: NCT05304767. Bethesda (MD)","author":"Therapeutics","year":"2022","journal-title":"Natl Libr Med (US)"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00839_bib104","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","article-title":"The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials","volume":"182","author":"Horan","year":"2025","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.neurot.2026.e00839_bib105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2024.08.001","article-title":"Efficacy of KarXT on negative symptoms in acute schizophrenia: a post hoc analysis of pooled data from 3 trials","volume":"274","author":"Horan","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/j.neurot.2026.e00839_bib106","article-title":"Bristol myers squibb announces topline results from phase 3 arise trial evaluating cobenfy (Xanomeline and trospium chloride) as an Adjunctive Treatment to Atypicsl Antipsychotics in Aults with Schizophrenia","year":"2025","journal-title":"Bristol Myers Squibb"},{"issue":"10369","key":"10.1016\/j.neurot.2026.e00839_bib107","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2026.e00839_bib108","series-title":"Emraclidine for schizophrenia fails to meet primary endpoints in phase 2 EMPOWER trials","author":"Kuntz","year":"2024"},{"key":"10.1016\/j.neurot.2026.e00839_bib109","series-title":"Cerevel investors' blood pressure relieved as safety data de-risks schizophrenia drug","author":"Armstrong","year":"2022"},{"key":"10.1016\/j.neurot.2026.e00839_bib110","article-title":"AbbVie revamps emraclidine expectations after mid-stage schizophrenia failure","author":"Armstrong","year":"2025","journal-title":"BioSpace"},{"key":"10.1016\/j.neurot.2026.e00839_bib111","series-title":"Neurocrine biosciences presents new positive data from phase 2 study of NBI-1117568 in adults with schizophrenia at the American society of clinical psychopharmacology 2025","author":"Biosciences","year":"2025"},{"key":"10.1016\/j.neurot.2026.e00839_bib112","series-title":"Anavex life sciences initiates placebo-controlled U.S. phase 2 clinical trial of ANAVEX\u00ae3-71 in schizophrenia","year":"2024"},{"key":"10.1016\/j.neurot.2026.e00839_bib113","series-title":"Anavex life sciences announces encouraging preliminary biomarker results from ongoing phase 2 study of ANAVEX\u00ae3-71 for the treatment of schizophrenia","year":"2024"},{"key":"10.1016\/j.neurot.2026.e00839_bib114","series-title":"MapLight therapeutics announces results from phase 1 trial of novel M1\/M4 muscarinic agonist in development for the treatment of schizophrenia and Alzheimer's disease psychosis","year":"2024"},{"key":"10.1016\/j.neurot.2026.e00839_bib115","series-title":"MapLight therapeutics announces completion of phase 1 clinical trial for ML-007, a novel therapy for the treatment of schizophrenia and dyskinesias","year":"2022"},{"key":"10.1016\/j.neurot.2026.e00839_bib116","series-title":"MapLight therapeutics announces initiation of phase 2 trial of its novel M1\/M4 muscarinic agonist ML-007C-MA for the treatment of schizophrenia","year":"2025"},{"key":"10.1016\/j.neurot.2026.e00839_bib117","series-title":"Syremis therapeutics launches with $165M to develop best-in-class medicines for mental health conditions","year":"2025"},{"key":"10.1016\/j.neurot.2026.e00839_bib118","series-title":"NeuShen therapeutics initiates first-in-human trial of NS-136, a novel selective M4 receptor positive allosteric modulator for the treatment of schizophrenia","year":"2024"},{"key":"10.1016\/j.neurot.2026.e00839_bib119","article-title":"Terran biosciences prepares for trials of schizophrenia drug","author":"Beaney","year":"2024","journal-title":"ClinicalTrialsArena"},{"issue":"24","key":"10.1016\/j.neurot.2026.e00839_bib120","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1016\/j.cell.2021.11.001","article-title":"From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease","volume":"184","author":"Brown","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2026.e00839_bib121","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","article-title":"Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease","volume":"4","author":"Voss","year":"2018","journal-title":"Alzheimer's Dement"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00839_bib122","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41386-018-0168-8","article-title":"TAK-071, a novel M(1) positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects","volume":"44","author":"Sako","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00839_bib123","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000214843","article-title":"Mechanisms of M3 muscarinic receptor regulation by wash-resistant xanomeline binding","volume":"83","author":"Noetzel","year":"2009","journal-title":"Pharmacology"},{"key":"10.1016\/j.neurot.2026.e00839_bib124","series-title":"Cobenfy [package insert]","year":"2024"},{"key":"10.1016\/j.neurot.2026.e00839_bib125","article-title":"Markers of muscarinic deficit for individualized treatment in schizophrenia","volume":"13","author":"Stuke","year":"2022","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.neurot.2026.e00839_bib126","doi-asserted-by":"crossref","DOI":"10.1038\/s44220-025-00529-w","article-title":"Preliminary real-world predictors of response to muscarinic targeting in psychosis","author":"Halassa","year":"2025","journal-title":"Nat Ment Health"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00839_bib127","doi-asserted-by":"crossref","first-page":"282","DOI":"10.9740\/mhc.2022.10.282","article-title":"Management of cognitive and negative symptoms in schizophrenia","volume":"12","author":"Maroney","year":"2022","journal-title":"Ment Health Clin"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00839_bib128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl Psychiatry"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:59:17Z","timestamp":1772855957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747926000097"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00839","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting muscarinic receptors for treating schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00839"}}